• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与托吡酯预防小儿偏头痛良好结局相关的因素

Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients.

作者信息

Yoo Il Han, Kim WooJoong, Kim Hunmin, Lim Byung Chan, Hwang Hee, Chae Jong Hee, Choi Jieun, Kim Ki Joong

机构信息

Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea.

Department of Pediatrics, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

出版信息

J Clin Neurol. 2017 Jul;13(3):281-286. doi: 10.3988/jcn.2017.13.3.281.

DOI:10.3988/jcn.2017.13.3.281
PMID:28748680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5532325/
Abstract

BACKGROUND AND PURPOSE

There are few studies that have investigated predictive factors related to migraine prophylaxis of which produced inconsistent results. The aim of this study was to identify factors that can predict the treatment response to topiramate prophylaxis in pediatric patients with migraine.

METHODS

One hundred and thirteen patients who were older than 7 years and received topiramate for at least 3 months were recruited from the Seoul National University Bundang Hospital outpatient clinic from 2005 to 2014. A positive response was defined as a reduction of more than 50% in the number of migraine episodes after topiramate treatment. Proposed predictive factors such as migraine characteristics including severity and frequency were assessed, as were other data on sex, disease duration, associated symptoms, family history, and impairment of daily activities.

RESULTS

Seventy patients (61.9%) responded to prophylactic treatment with topiramate. Patients who experienced significant impairment in daily activities showed significant benefit from the treatment (p=0.004). Sex, the severity, frequency, and duration of migraine episodes, disease duration, treatment duration, age at onset, and associated symptoms were not significantly related to a response to topiramate treatment.

CONCLUSIONS

Migraine characteristics and associated symptoms were not significantly related to a response to topiramate treatment. However, patients with significant impairment in daily activities showed significant benefit from the treatment, and so prophylactic topiramate treatment should be strongly encouraged in this patient group.

摘要

背景与目的

很少有研究调查与偏头痛预防性治疗相关的预测因素,且结果并不一致。本研究旨在确定可预测偏头痛患儿托吡酯预防性治疗反应的因素。

方法

从2005年至2014年,从首尔国立大学盆唐医院门诊招募了113名年龄大于7岁且接受托吡酯治疗至少3个月的患者。阳性反应定义为托吡酯治疗后偏头痛发作次数减少超过50%。评估了诸如偏头痛特征(包括严重程度和频率)等拟议的预测因素,以及关于性别、病程、相关症状、家族史和日常活动受损情况的其他数据。

结果

70名患者(61.9%)对托吡酯预防性治疗有反应。日常活动有显著受损的患者从治疗中获益显著(p = 0.004)。性别、偏头痛发作的严重程度、频率和持续时间、病程、治疗持续时间、发病年龄和相关症状与托吡酯治疗反应无显著相关性。

结论

偏头痛特征和相关症状与托吡酯治疗反应无显著相关性。然而,日常活动有显著受损的患者从治疗中获益显著,因此应强烈鼓励该患者群体进行托吡酯预防性治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73e/5532325/9fbf461ec504/jcn-13-281-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73e/5532325/9fbf461ec504/jcn-13-281-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73e/5532325/9fbf461ec504/jcn-13-281-g001.jpg

相似文献

1
Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients.与托吡酯预防小儿偏头痛良好结局相关的因素
J Clin Neurol. 2017 Jul;13(3):281-286. doi: 10.3988/jcn.2017.13.3.281.
2
Effective dose of topiramate in pediatric migraine prophylaxis.托吡酯在儿童偏头痛预防中的有效剂量。
J Pediatr Neurosci. 2012 Sep;7(3):171-4. doi: 10.4103/1817-1745.106470.
3
Predictors of a negative response to topiramate therapy in patients with chronic migraine.慢性偏头痛患者托吡酯治疗阴性反应的预测因素。
Headache. 2005 Jul-Aug;45(7):932-5. doi: 10.1111/j.1526-4610.2005.05161.x.
4
Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.托吡酯预防偏头痛、转化型偏头痛和丛集性头痛。
Headache. 2002 Sep;42(8):796-803. doi: 10.1046/j.1526-4610.2002.02183.x.
5
Topiramate as an adjunctive treatment in migraine prophylaxis.托吡酯作为偏头痛预防性治疗的辅助用药。
Headache. 2003 Nov-Dec;43(10):1080-4. doi: 10.1046/j.1526-4610.2003.03209.x.
6
Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.两种中心、随机的偏头痛预防方案对照研究,比较了采用预防性氟伐曲坦或每日托吡酯的方案:研究和临床意义。
Headache. 2012 May;52(5):749-64. doi: 10.1111/j.1526-4610.2011.02054.x. Epub 2011 Dec 21.
7
Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial.托吡酯单药及托吡酯联合维生素D3预防儿童偏头痛的疗效:一项随机临床试验
Iran J Child Neurol. 2020 Fall;14(4):77-86.
8
Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.托吡酯与阿米替林预防偏头痛的比较:一项针对成年偏头痛患者的26周多中心随机双盲双模拟平行组非劣效性试验。
Clin Ther. 2009 Mar;31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020.
9
The efficacy and safety of topiramate for prophylaxis of migraine in children.托吡酯用于儿童偏头痛预防的疗效与安全性。
Iran J Child Neurol. 2013 Fall;7(4):7-11.
10
Outcomes of topiramate for prophylaxis of chronic migraine headache.托吡酯预防慢性偏头痛的疗效
Pak J Med Sci. 2022 Jul-Aug;38(6):1606-1610. doi: 10.12669/pjms.38.6.5616.

引用本文的文献

1
Pediatric Episodic Migraine with Aura: A Unique Entity?小儿发作性偏头痛伴先兆:一种独特的病症?
Children (Basel). 2021 Mar 17;8(3):228. doi: 10.3390/children8030228.
2
Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial.托吡酯单药及托吡酯联合维生素D3预防儿童偏头痛的疗效:一项随机临床试验
Iran J Child Neurol. 2020 Fall;14(4):77-86.
3
Baseline Brain Gray Matter Volume as a Predictor of Acupuncture Outcome in Treating Migraine.基线脑灰质体积作为针刺治疗偏头痛疗效的预测指标

本文引用的文献

1
Pediatric Headache.小儿头痛
Continuum (Minneap Minn). 2015 Aug;21(4 Headache):1132-45. doi: 10.1212/CON.0000000000000197.
2
Preventive Migraine Treatment.预防性偏头痛治疗
Continuum (Minneap Minn). 2015 Aug;21(4 Headache):973-89. doi: 10.1212/CON.0000000000000199.
3
Migraine in a pediatric population: a clinical study in children younger than 7 years of age.儿科人群中的偏头痛:一项针对7岁以下儿童的临床研究。
Front Neurol. 2020 Mar 5;11:111. doi: 10.3389/fneur.2020.00111. eCollection 2020.
4
Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs.有先兆偏头痛和无先兆偏头痛治疗反应的差异:来自临床实践和 RCT 的经验教训。
J Headache Pain. 2019 Sep 6;20(1):96. doi: 10.1186/s10194-019-1046-4.
Dev Med Child Neurol. 2015 Jun;57(6):585-8. doi: 10.1111/dmcn.12679. Epub 2015 Jan 14.
4
Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain.偏头痛的病理生理学:三叉神经血管通路的解剖结构及相关神经症状、皮层扩散性抑制、疼痛敏化与调制
Pain. 2013 Dec;154 Suppl 1. doi: 10.1016/j.pain.2013.07.021.
5
Predicting prognostic factors in a randomized controlled trial of acupuncture versus topiramate treatment in patients with chronic migraine.预测针灸与托吡酯治疗慢性偏头痛患者的随机对照试验中的预后因素。
Clin J Pain. 2013 Nov;29(11):982-7. doi: 10.1097/AJP.0b013e31827eb511.
6
Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines.氟桂利嗪与托吡酯预防儿童偏头痛的比较。
Eur J Paediatr Neurol. 2013 Jan;17(1):45-9. doi: 10.1016/j.ejpn.2012.10.001. Epub 2012 Oct 27.
7
Canadian Headache Society guideline for migraine prophylaxis.加拿大头痛学会偏头痛预防指南。
Can J Neurol Sci. 2012 Mar;39(2 Suppl 2):S1-59.
8
Pediatric headache: update on recent research.小儿头痛:近期研究进展。
Headache. 2012 Feb;52(2):327-32. doi: 10.1111/j.1526-4610.2011.02085.x. Epub 2012 Jan 30.
9
Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey.韩国学龄儿童原发性头痛的患病率及临床特征:一项全国性调查。
Headache. 2012 Apr;52(4):592-9. doi: 10.1111/j.1526-4610.2011.02001.x. Epub 2011 Sep 19.
10
Childhood abuse and migraine: epidemiology, sex differences, and potential mechanisms.儿童期虐待与偏头痛:流行病学、性别差异及潜在机制。
Headache. 2011 Jun;51(6):869-79. doi: 10.1111/j.1526-4610.2011.01906.x.